Pubdate: Sat, 15 Dec 2007
Source: Willits News (CA)
Copyright: 2007 Willits News
Contact:  http://www.willitsnews.com/
Details: http://www.mapinc.org/media/4085
Author: Linda Williams, TWN Staff Writer
Photo: A residential pot grow in the Ukiah area. [Mendocino County 
Sheriff's Department photo] http://www.mapinc.org/images/ukiahpotgrow.jpg
Referenced: The Institute of Medicine report 
http://www.nap.edu/readingroom/books/marimed/
Referenced: The Canadian Senate report http://drugsense.org/url/70Hm6AaU
Cited: University of California's Center for Medicinal Cannabis 
Research http://www.cmcr.ucsd.edu/geninfo/index.htm
Bookmark: http://www.mapinc.org/mmj.htm (Marijuana - Medicinal)

MARIJUANA AND MEDICAL SCIENCE

The rhetoric surrounding marijuana, or cannabis sativa, as medicine 
ranges from calling it everything from "the killer weed" to "the 
miracle drug." Each side in the debate pulls snippets from scientific 
studies to confirm or rebut their point of view. One need only review 
information provided by groups like the National Organization for 
Reform of Marijuana Laws or the White House policy room to see this effect.

The most comprehensive look at the issue to date is Marijuana and 
Medicine: Assessing the Science Base, conducted by the U.S. Institute 
of Medicine and published in 1999. With minimal research being 
conducted in the U.S. on marijuana as medicine, in 2000, the 
California Legislature created the University of California's Center 
for Medicinal Cannabis Research in San Diego. The center was tasked 
to assess the use of cannabis as an alternative for treating specific 
medical conditions.

Research is now being conducted in institutions around the world, 
trying to unlock the potential medical benefits of compounds called 
cannabinoids found in cannabis sativa. A summary of research 
published in 2007 is at the end of the article.

One of the spurs to this increased interest was the discovery in the 
1990s of special receptors in different areas of the brain, which 
respond to cannabinoids. This led to the identification of a 
substances created naturally by the body that resemble THC the main 
active ingredient in marijuana.

Most people smoke marijuana to get "high." This high provides a 
"sense of well-being or euphoria and increased talkativeness and 
laughter alternating with periods of introspective dreaminess 
followed by lethargy and sleepiness. A characteristic feature of a 
marijuana 'high' is a distortion in the sense of time associated with 
deficits in short-term memory and learning. A marijuana smoker 
typically has a sense of enhanced physical and emotional sensitivity, 
including a feeling of greater interpersonal closeness. The most 
obvious behavioral abnormality displayed by someone under the 
influence of marijuana is difficulty in carrying on an intelligible 
conversation, perhaps because of an inability to remember what was 
just said even a few words earlier," according to the 1999 IOM study.

"Although marijuana smoke delivers THC and other cannabinoids to the 
body, it also delivers harmful substances, including most of those 
found in tobacco smoke. In addition, plants contain a variable 
mixture of biologically active compounds and cannot be expected to 
provide a precisely defined drug effect. For those reasons, there is 
little future in smoked marijuana as a medically approved 
medication," concluded the IOM study.

The study further concluded that for some patients, such as the 
terminally ill, if marijuana would possibly benefit the patient, the 
long-term risk was "not of great concern."

For other patients, the study advised that physicians could consider 
marijuana for a narrow range of short term health issues such as AIDs 
wasting diseases, severe nausea and vomiting associated with cancer 
and its treatment and relief of neuropathic pain. While the study 
concluded marijuana had the potential in some patients to relieve the 
symptoms, the study also suggested stringent guidelines for 
physicians recommending marijuana to their patients.

The prescription guidelines were established to relieve symptoms 
considered debilitating such as intractable pain or vomiting. The key 
points were for marijuana to be tried after all approved medications 
had failed to provide relief; the prescription be for less than six 
months; a follow up program be implemented to assess effectiveness; 
and the recommendation be supported by an oversight review board 
within the hospital or clinic.

For chronic debilitating conditions such as pain or AIDS wasting, the 
IOM study recognized that the issues of long-term medical use of 
marijuana was more complex.  Patients who had exhausted the other 
available medical options could not be reasonably expected to wait 
until some time in the unknown future for someone to isolate and 
synthesize the precise cannabinoid drug cocktail that provided the 
best benefit or to develop a "nonsmoked rapid-onset cannabinoid drug 
delivery system."

Since the IOM study, a number of vaporizers, which claim to provide 
the user with the benefit of marijuana without the hazard of the 
smoke, have been developed. A recent pilot study tested one such 
device on 18 healthy volunteers and concluded it had the potential to 
provide the benefit of marijuana without the toxic smoke.

The psychoactive effects of marijuana make it difficult for users to 
function in society while on a marijuana high. Those desiring to 
operate a vehicle or machinery, conduct a conversation, get to work 
on time, stay awake or learn new things may find it difficult to 
conduct routine business while high on marijuana. These side effects 
were found particularly hard for patients not already familiar with 
marijuana use.

Other physiological effects from marijuana use such as increased 
heart rate and its effects on blood pressure make it a concern for 
older patients already suffering from heart disease, potentially 
leading to heart attacks or other cardiovascular event.

Medical Treatments

A review of the literature shows that very few rigorous studies have 
been conducted on the use of marijuana to treat disease. While 
cannabinoid receptor locations in the brain offer some insight into 
which diseases may be helped by drugs developed from marijuana, most 
studies have involved few participants and were not conducted 
following traditionally recognized methods for evaluating treatments. 
Despite this, some synthetic derivatives from marijuana are now 
available and are being prescribed to patients for specific ailments.

A large part of the medical research community has recommended 
increased research into how marijuana compounds can be harnessed to 
reduce suffering while minimizing any negative effects.

Despite recognizing the substantial potential for future benefit, the 
IOM study believed that only a small group of patients would actually 
benefit from using marijuana. The study observed that for most 
symptoms marijuana was being considered to treat there were other 
more effective treatment options, which most patients responded to.

For cancer patients undergoing chemotherapy, the study found the 
public was not aware of the major strides made in medicine to treat 
nausea and side effects.  While cannabinoid substances were only 
effective in 24 percent of the cases, a combination of currently 
available drugs is considered nearly 100 percent effective if started 
before chemotherapy begins.  Because pills are less effective once a 
patient starts vomiting, an inhaled fast acting drug, such as the THC 
from marijuana could provide some benefit.

For HIV patients, while marijuana may provide some relief from 
wasting diseases it has also been linked to suppressing the immune 
system. For unknown reasons the relative 12-year risk of death from 
marijuana smokers with HIV is nearly twice that of those not using 
it.  Many HIV patients are effectively taking synthetic derivatives 
of marijuana for wasting diseases.

In a 2003, 23 percent of HIV patients in a public health study in San 
Mateo used marijuana. Of those users, only 17 percent met the strict 
definition of medical marijuana use for the relief of nausea, 
anorexia or pain. Some used a synthetic to treat AIDS wasting and 
smoked marijuana recreationally.

Marijuana is no longer believed by most to be an effective treatment 
for glaucoma. While it does temporarily reduce the pressure within 
the eye, it acts for a short period of time and reduces the blood 
flow to the optic nerve, potentially damaging it. Other treatments 
are now considered significantly more effective in managing glaucoma.

For multiple sclerosis, the studies have not shown marijuana to be 
particularly effective in managing the pain, spasticity or the 
disease. Studies have had mixed results, although the cannabinoid 
receptors are particularly abundant in areas of the brain controlling 
movement so further study is being conducted.

2007 Research Developments

Some new studies show the importance of being able to deliver 
predictable and repeatable dosages of THC to patients and clearly 
established that more is not always better.

A study of 15 healthy volunteers found that medium doses of marijuana 
relieved some neuropathic pain in healthy volunteers while higher 
doses actually made the pain worse. Neuropathic pain is associated 
with cancer, AIDS, diabetes, etc. Low doses had no effect. Report 
published in October 2007

While low doses of THC seem to alleviate depression, higher doses 
makes the depression worse, concluded McGill University researchers 
in a report published in October 2007.

These studies show the value of being able to control and adjust the 
amount of THC delivered to a patient to get the desirable outcome.

Other Developments

Foot pain associated with HIV (neuropathic) shows some relief from 
smoking marijuana over a placebo according to a study in February 2007.

Smoking one joint causes the same lung damage as three to five 
tobacco cigarettes according to an August 2007 Danish study.

A cannabinoid called CDB in marijuana has shown early promise in 
laboratory tests for treating metastatic forms of breast cancer. Very 
small quantities of CDB are present naturally in marijuana. Published 
in November 2007.

THC may help the virus causing Kaposi's sarcoma both infect healthy 
cells and then multiply according to a study conducted by Harvard 
Medical School researchers and published in August 2007. Kaposi's 
sarcoma is a cancer affecting those with depressed immune systems 
such as HIV and transplant patients.

A team of Swedish researchers has identified how the brains of unborn 
babies are damaged by mothers smoking marijuana, published in May 2007.

Harvard researchers have shown in lab and mice studies that certain 
THC treated lung cancer cells grew at half the rate of untreated 
cells, published in April 2007.

Research done in Cardiff University in Wales, suggests that marijuana 
use could increase the risk of developing psychotic illness later in 
life by 40 percent, published in August 2007.

THC may help reduce the symptoms of allergic skin disease according 
to study on mice by an international group of researchers published 
in August 2007.

GW Pharmaceuticals in Britain has been conducting tests for eight 
years on Sativex, a prescription drug derived from cannabis to 
relieve symptoms of neuropathic dysfunction and pain. The drug is 
being reviewed in Canada for market approval.

[sidebar]

EDITOR'S NOTE - Information on the medical effects of marijuana was 
gleaned from research published in a variety of scientific journals. 
The basis of much of the article came from the Institute of Medicine 
Marijuana and Medicine study published in 1999, which was requested 
by White House Office of National Drug Control Policy in 1997. While 
the study is much referenced by medical marijuana support groups, it 
is less quoted in White House drug policy. The IOM is one of four US 
National Academies and is a not-for-profit and non-governmental 
agency established as an independent think tank to advise the nation 
on matters concerning health and medicine. It remains the most 
comprehensive treatise available on the issue. The Canadian Senate 
authored a similar study in 2002 that mirrored much of the IOM 
findings. Many of these findings were also supported by several 
sponsored reports from the UC Center for Medical Cannabis Research 
and the Medical Board of California marijuana policy. An effort was 
made to focus this article on the science associated with marijuana's 
medical value and not explore other medical marijuana issues. 
- ---
MAP posted-by: Richard Lake